Halozyme Therapeutics (NASDAQ:HALO) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research report sent to investors on Wednesday, Benzinga reports. HC Wainwright currently has a $50.00 price target on the biopharmaceutical company’s stock.

HALO has been the subject of a number of other reports. StockNews.com upgraded Halozyme Therapeutics from a hold rating to a buy rating in a research report on Friday, February 23rd. Benchmark reiterated a buy rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday. TD Cowen began coverage on Halozyme Therapeutics in a research report on Thursday, February 29th. They issued an outperform rating and a $54.00 price objective for the company. TheStreet lowered Halozyme Therapeutics from a b- rating to a c+ rating in a research report on Monday, January 22nd. Finally, JMP Securities reiterated a market outperform rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, February 21st. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of Moderate Buy and a consensus target price of $53.29.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $38.02 on Wednesday. Halozyme Therapeutics has a twelve month low of $29.85 and a twelve month high of $45.00. The firm has a market cap of $4.83 billion, a PE ratio of 18.02, a price-to-earnings-growth ratio of 0.46 and a beta of 1.25. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. The business has a fifty day moving average of $39.44 and a 200-day moving average of $37.76.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. On average, equities research analysts predict that Halozyme Therapeutics will post 3.33 EPS for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total transaction of $384,900.00. Following the transaction, the senior vice president now owns 168,176 shares in the company, valued at $6,473,094.24. The sale was disclosed in a document filed with the SEC, which is available through this link. Over the last quarter, insiders have sold 30,000 shares of company stock worth $1,196,800. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors have recently modified their holdings of HALO. TD Asset Management Inc lifted its holdings in shares of Halozyme Therapeutics by 517.0% during the 4th quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock valued at $73,326,000 after purchasing an additional 1,662,390 shares in the last quarter. Norges Bank bought a new position in shares of Halozyme Therapeutics during the 4th quarter valued at about $44,935,000. Epoch Investment Partners Inc. lifted its holdings in shares of Halozyme Therapeutics by 250.5% during the 4th quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock valued at $42,986,000 after purchasing an additional 831,199 shares in the last quarter. Macquarie Group Ltd. lifted its holdings in shares of Halozyme Therapeutics by 22.8% during the 1st quarter. Macquarie Group Ltd. now owns 3,200,481 shares of the biopharmaceutical company’s stock valued at $122,226,000 after purchasing an additional 595,220 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Halozyme Therapeutics by 174.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock valued at $33,894,000 after purchasing an additional 563,989 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.